Nothing Special   »   [go: up one dir, main page]

Hu et al., 2018 - Google Patents

A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistance

Hu et al., 2018

View HTML @Full View
Document ID
7084408209534326950
Author
Hu H
Zhao X
Kaushik S
Robillard L
Barthelet A
Lin K
Shah K
Simmons A
Raponi M
Harding T
Bandyopadhyay S
Publication year
Publication venue
Cell reports

External Links

Snippet

Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited. We report the generation of a quantitative chemical-genetic interaction map in human mammary epithelial cells charting …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Similar Documents

Publication Publication Date Title
Hu et al. A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistance
Peng et al. Genome-wide transcriptome profiling of homologous recombination DNA repair
Srivas et al. A network of conserved synthetic lethal interactions for exploration of precision cancer therapy
Matulonis et al. Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials
Camidge et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
Yoon et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach
Takahashi et al. Replication stress defines distinct molecular subtypes across cancers
Yang et al. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature)
Guerrero Llobet et al. An mRNA expression-based signature for oncogene-induced replication-stress
Lokeshwar et al. Molecular oncology of bladder cancer from inception to modern perspective
Han et al. Genetic interaction-based biomarkers identification for drug resistance and sensitivity in cancer cells
Papalouka et al. DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival
Gu et al. A landscape of synthetic viable interactions in cancer
Sun et al. Cell cycle arrest is an important mechanism of action of compound Kushen injection in the prevention of colorectal cancer
Ryan et al. Complex synthetic lethality in cancer
Yu et al. A meta‐analysis: micro RNA s’ prognostic function in patients with nonsmall cell lung cancer
Qin et al. Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration‐resistant prostate cancer
Li et al. Comprehensive analysis reveals USP45 as a novel putative oncogene in pan-cancer
Chan et al. Clinical implications of systemic and local immune responses in human angiosarcoma
Kang et al. Aberrant transcript usage is associated with homologous recombination deficiency and predicts therapeutic response
Aprile et al. Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
Orme et al. Co-occurring BRCA2/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer
Joy et al. AKT pathway genes define 5 prognostic subgroups in glioblastoma
Shan et al. A novel epithelial‐mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer
Belcastro et al. Systematic verification of upstream regulators of a computable cellular proliferation network model on non-diseased lung cells using a dedicated dataset